Research programme: ion channel, G protein-coupled receptor and kinase modulators - Amgen/BioFocus

Drug Profile

Research programme: ion channel, G protein-coupled receptor and kinase modulators - Amgen/BioFocus

Latest Information Update: 07 Apr 2014

Price : $50

At a glance

  • Originator Amgen; BioFocus DPI
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Ion channel modulators; Phosphotransferase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Inflammation; Neurological disorders

Most Recent Events

  • 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
  • 22 Mar 2010 Preclinical development is ongoing in United Kingdom
  • 18 Dec 2008 BioFocus and Amgen extend their discovery collaboration through 2009 and 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top